# EDGAR Filing Document

**Accession Number:** 0000949858
**File Stem:** 0000950170-25-083214
**Filing Date:** 2025-6
**Character Count:** 6984
**Document Hash:** 68e19a63e29c4e4b82c5bab8c7925cea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-083214.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0000950170-25-083214

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACHIEVE LIFE SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000949858
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954343413
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 033-80623
- **FILM NUMBER:** 251031816

**BUSINESS ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021
- **BUSINESS PHONE:** 425-686-1500

**MAIL ADDRESS:**
- **STREET 1:** 22722 29TH DR. SE
- **STREET 2:** SUITE 100
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ONCOGENEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20080821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SONUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19950825

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** June 4, 2025

------

ACHIEVE LIFE SCIENCES, INC.

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;033-80623 | 95-4343413 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(State or Other Jurisdiction**<br>**of Incorporation)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 22722 29th Drive SE**,** Suite 100<br>Bothell**,** WA | 22722 29th Drive SE**,** Suite 100<br>Bothell**,** WA | 98021 |
| 1040 West Georgia**,** Suite 1030<br>Vancouver**,** B.C**.,** Canada  | 1040 West Georgia**,** Suite 1030<br>Vancouver**,** B.C**.,** Canada  | V6E 4H1 |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (**604**)** 210-2217

**N/A** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**<u>Title of each class</u>** | &nbsp;&nbsp;**<u>Trading Symbol</u>** | &nbsp;&nbsp;**<u>Name of exchange on which registered</u>** |
| &nbsp;&nbsp;Common Stock, par value $0.001 per share | &nbsp;&nbsp;ACHV | &nbsp;&nbsp;The NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The Annual Meeting of Stockholders of Achieve Life Sciences, Inc. (the "Company") was held on June 4, 2025. The following is a brief description of each matter voted upon and the certified voting results.

(1)Election of seven directors to serve until the Company's next annual meeting or until the directors' successors are duly elected and qualified:

---

| | | | |
|:---|:---|:---|:---|
|  | **For** | **Withhold** | **Broker<br>Non-Votes** |
| Stuart Duty | 14686624 | 410433 | 11422484 |
| Bridget Martell | 12956648 | 2140409 | 11422484 |
| Thomas B. King | 14716175 | 380882 | 11422484 |
| Thomas Sellig | 13038445 | 2058612 | 11422484 |
| Richard Stewart | 14727815 | 369242 | 11422484 |
| Nancy R. Phelan | 14859492 | 237565 | 11422484 |
| Kristen Slaoui | 14858417 | 238640 | 11422484 |

---

Pursuant to the foregoing votes, the nominees listed above were elected as directors to serve on the Company's board of directors.

(2)Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Broker**<br>**Non-votes** |
| 26,459,791 |  | 53,879 | 5,871 |  |

---

Pursuant to the foregoing votes, the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.

(3)Approval of an amendment to the Company's 2023 Non-Employee Director Equity Incentive Plan to increase the number of shares available for issuance thereunder:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **For** | **Against** | **Against** | **Abstain** | **Broker**<br>**Non-votes** |
| 6,736,105 |  | 7,982,633 | 378,319 | 11,422,484 |

---

Pursuant to the foregoing votes, the amendment of the Company's 2023 Non-Employee Director Equity Incentive Plan was not approved.

________________________

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;ACHIEVE LIFE SCIENCES, INC. |
| &nbsp;&nbsp; <br>Date: June 6, 2025 | &nbsp;&nbsp; <br>/s/ Mark Oki |
|  | &nbsp;&nbsp;Mark Oki<br>Chief Financial Officer (Principal Financial Officer) |

---

------